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Abstract
Background: there are around 100,000 new stroke cases and over a million people living with its consequences annually in
the UK.This has large impacts on health and social care, unpaid carers and lost productivity. We aimed to estimate associated
costs.
Methods: we estimated 2014/2015 annual mean cost per person and aggregate UK cost of stroke for individuals aged ≥40
from a societal perspective. Health and social care costs in the first and subsequent years after stroke were estimated from
discrete event simulation modelling, with probability of progression and length of receipt of different health and social care
services obtained from routine registry and audit data. Unpaid care hours and lost productivity were obtained from trial data.
UK unit costs were applied to estimate mean costs. Epidemiological estimates of stroke incidence and prevalence were then
applied to estimate aggregate costs for the UK.
Results:mean cost of new-onset stroke is £45,409 (95%CI 42,054-48,763) in the first year after stroke and £24,778 (20,234–
29,322) in subsequent years. Aggregate societal cost of stroke is £26 billion per year, including £8.6 billion for NHS and social
care. The largest component of total cost was unpaid care (61%) and, given high survival, £20.6 billion related to ongoing
care.
Conclusion: the estimated aggregate cost of stroke substantially exceeds previous UK estimates. Since most of the cost is
attributed to unpaid care, interventions aimed at rehabilitation and reducing new and recurrent stroke are likely to yield
substantial benefits to carers and cost savings to society.
Keywords: burden, cost, economic, older people, simulation, stroke
Key Points
• There are around 100,000 new stroke cases and over a million people living with its consequences each year in the UK.
• On average, new onset strokes cost £45 k in the first year & £25 k in subsequent years, totalling £26 billion per year (UK).
• Interventions for rehabilitation and reducing new and recurrent stroke could yield substantial benefits and savings.
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Introduction
The global lifetime risk of stroke is approximately 25%
from the age of 25 years [1], making it the second largest
cause of death worldwide and fourth in the UK. There
are over 113,000 new strokes annually in the UK [2], a
quarter of which occur among the under 65 s [3]. Many
of the estimated 950,000 stroke survivors [4] experience
significant and long-term residual physical and psychological
impacts, repeat strokes, transient ischaemic attacks and/or
death within a year of stroke. [3] Stroke prevention and
treatment, and its morbidity and mortality impacts, carry
economic consequences across society [5,6]. Despite signif-
icant progress in prevention, treatment and rehabilitation,
there is a great capacity for further improvements and thus
reduced economic impacts. This is ever more important
given pressures faced by both formal and unpaid care sectors.
Understanding the scale and range of consequences can
help prioritize scarce resources. The annual societal cost of
stroke in the UK has previously been estimated at £9 billion
(2005 prices), with over half attributed to lost employment
and unpaid (‘informal’) care [5]. There is a need for updated
estimates to ensure future service, and policy responses can
be discussed in the context of timely and relevant data.
Methods
We synthesized data from multiple sources to estimate
annual mean cost per person and the aggregate UK cost
of stroke affecting individuals aged ≥40 years. A societal
perspective incorporated formal health and social care
(hospitals, community care and care homes), unpaid care
and lost productivity arising due to stroke-related morbidity
and early mortality. Costs in the year following a first-stroke
episode formed the basis for costs of incident (new) stroke,
while annual costs in subsequent years represented costs of
prevalent stroke (stroke survivors). Mean costs were further
gauged by sex, age (40–64, 65–74, 75–84, ≥85 years),
stroke type (ischaemic or haemorrhagic) and stroke severity
(National Institutes of Health Strokes Score (NIHSS) 1–2
for no/mild stroke (NIHSS score of 0–4), 3 for moderate
stroke (scores 5–15) and 4–5 for severe stroke (scores
16–42)). Reported costs are for the 2014/2015 cost year
in Great British Pound Sterling (GBP, £).
Average cost of formal health and social care
Estimates for National Health Service (NHS) and Personal
Social Services (PSS) costs were obtained using a modified
version of a cost-of-illness model [7,8] developed by the
National Guideline Centre (NGC) and the Sentinel Stroke
National Audit Programme (SSNAP) at the Royal College
of Physicians (RCP) on behalf of NHS England. They used
data from SSNAP (April 2013—March 2015; n = 111,846)
and the South London Stroke Register (SLSR) to inform a
discrete event simulation (DES) model, which represented
the probability of progression and length of stay in vari-
ous settings in the stroke pathway, conditional on patient
characteristics. The pathway started with admission to a
hospital acute stroke unit. Subsequent progression to other
settings (stroke unit, early supported discharge, commu-
nity rehabilitation), discharge (to care home or own home)
or death was conditional on individual factors, such as
age, sex and stroke severity. Upon discharge from hospital,
the patient’s journey continues through repeat strokes, care
home admission or death. Stroke services included in the
model are detailed by Xu et al . [7,8] and are summarized
in Figure 1 and Supplementary Appendix 1.
We modified the NGC model to generate separate esti-
mates for incident and prevalent stroke. Cross-sectional data
collection points were changed from 1 and 5 years post-
stroke to 1, 2, 3 and 4 years post-stroke. Costs incurred in the
first 12 months were then attributed to incident stroke and
average costs incurred in years 2, 3 and 4 were used as a proxy
for prevalent stroke. Costs incurred in years 2, 3 and 4 post-
stroke were adjusted for the proportion of patients alive at
the start of the corresponding year to avoid underestimating
the true cost of follow-up care of stroke survivors. Unit costs
were also updated (see below).
Average cost of unpaid care
Costs of care provided by family and other unpaid carers were
estimated using control arm data from two large UK-based
randomized controlled stroke rehabilitation trials: TRACS
[9] and LoTS Care [10]. Both provided self-reported data at
6 and 12months post-recruitment on number of hours spent
by all resident and non-resident unpaid carers on personal
care and a range of other tasks such as preparing meals,
gardening and help with managing finances. Neither trial
sought to assess inputs specifically attributable to stroke due
to the difficulties in doing so but did ask respondents to
report assistance received due to illness/injury over and above
any help they received normally. For stroke incidence costs,
we used unpaid care hours over the full 12-month period
from the TRACS trial; for stroke prevalence costs, we used
unpaid care hours from only the last 6 months of follow-
up from the LoTS Care trial to better reflect longer-term
inputs (the trial recruited patients at hospital discharge, thus
data collected at 12 months post-recruitment [covering the
previous 6 months] relates at least partially to the period
beyond 1 year post-stroke).
Since the requirement for a primary unpaid carer for
inclusion in TRACS risked over-estimating unpaid care
inputs for our purposes, we used the trial’s participant inclu-
sion flow chart [11] to determine the proportion of patients
screened but excluded for absence of a primary carer, and
added the equivalent proportion of simulated participants
into the model. Mean unpaid care costs for these additional
patients were assumed as 25% of those for people with a
primary carer.
Average cost of lost productivity
LoTS Care trial data [10] were also used for estimating
lost productivity. We used data on changed employment
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Figure 1. Pathways represented in the NGC model.
status (e.g. moving from full- to part-time working, or not
working) and mortality 6 months after stroke for stroke
incidence costs and the equivalent figures at 12 months
for stroke prevalence costs. Number of hours spent in full-
(37.6 hours per week) and part-time (16.2 hours per week)
work were assumed from national data [12].
Unit costs
Unit costs (Supplementary Appendix 2) for health and
social care were derived from published UK sources for the
2014/2015 financial year [13–15].
National aggregate costs and estimates of
incidence and prevalence
To derive the aggregate cost of stroke in the UK, we multi-
plied estimatedmean cost of incident and prevalent stroke by
estimated absolute incidence and prevalence. These in turn
were calculated by combining age-specific incidence and
prevalence rates per 1,000 people reported in literature with
mid-2016 age-specific population figures [17] for adults aged
≥40 years; this accounted for changes in the age structure of
the UK population.
A focused review of UK studies identified three key
studies each for stroke incidence [2,18,19] and prevalence
[4,20,21]. We excluded three incidence studies for inclusion
of transient ischaemic attack [22,23] and focused only on
ischaemic stroke [24].
From included studies, we estimated stroke incidence in
2015 ranged from 113,400 to 119,100, with a potential
range from 85,800 to 147,600 when using low and high
estimates reported in individual studies (We later used these
ranges in our sensitivity analyses—see below.) As a point
estimate, we focused on the mid-point estimate of 117,600
[19].
Similarly, we estimated stroke prevalence ranged from
950,000 to 1.3 million, or 797,000 to 1.4 million when
accounting for reported ranges. In estimating ranges for
stroke prevalence, we adjusted numbers from individual
studies to represent the full population of interest e.g. Ged-
des et al . [4] only sampled individuals aged ≥55 years, so
we used estimates from O’Mahony et al . [21] to generate
estimates for younger adults. As the mid-point estimate of
1,002,600 reported by Jagger et al . [20] was from a simu-
lation and based on old data (1991–1994), we instead used
Geddes et al .’s [4] figure (950,200; based on n = 18,827) for
our point estimate.
Analysis of uncertainty
Estimates of mean cost produced by a DES model can be
influenced by sampling variation across individuals within
272
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/a
g
e
in
g
/a
rtic
le
-a
b
s
tra
c
t/4
9
/2
/2
7
0
/5
6
7
9
6
8
4
 b
y
 g
u
e
s
t o
n
 1
8
 M
a
rc
h
 2
0
2
0
Estimated societal costs of stroke in the UK based on a discrete event simulation
the model, particularly in subgroups containing small
patient numbers (i.e. Monte Carlo error). To minimize
individual-level uncertainty and obtain stable estimates
of 95% confidence intervals (CI) for mean cost, input
values were repeatedly sampled over a large number of
iterations. Repeated testing and validation determined that
500 replications of the model output with 4,000 individuals
per run were necessary to achieve stable values for the point
estimate and standard error.
To determine the effect of uncertainty around individual
parameters, we used one-way sensitivity analyses to vary
values such as assumed length of stay in stroke units and
transition probabilities (Supplementary Appendix 3).
Uncertainty in aggregate cost estimates was gauged by
substituting lower and upper estimates of incidence and
prevalence and by applying 95% CI for mean cost in each
cost category derived from the NGC model.
Results
Mean costs of stroke
The mean annual cost per person from an NHS and PSS
perspective in the first year post-stroke is £18,081 (95%
CI 17,621–18,542) with £13,269 (95%CI 13,058–13,480)
and £4,812 (95%CI 4,434–5,190) attributable to NHS and
PSS, respectively (Table 1). Annual NHS and PSS costs for
subsequent years total £7,759 (95% CI 7,200–8,318), but
a greater portion becomes attributable to PSS rather than
NHS care (£5,544 versus £2,215).
The mean annual cost of unpaid care is £25,897 (95%
CI 23,621–28,173) and £15,354 (95% CI 12,501–18,656)
in the first and subsequent years after stroke respectively.
For lost productivity, respective costs are £1,431 (95% CI
813–2,049) and £1,666 (95% CI 983–2,349); individuals
aged 40–64 years (more likely to be of working age) had
highest lost productivity costs (£5,172 per stroke case in
the first year, £5,895 in subsequent years). Supplementary
Appendices 4–7 provide further breakdowns for unpaid care
and lost productivity.
Combining mean costs for NHS, PSS, unpaid care and
lost productivity, the total mean cost of stroke from a soci-
etal perspective was £45,409 (42,054–48,763) in the first
12 months after stroke and £24,778 (20,234–29,322) in
subsequent years.
Unit cost and length of stay in acute stroke units, proba-
bility of repeat stroke and probability of care home admission
had a significant impact on costs estimates (Supplementary
Appendix 3).
Aggregate cost of stroke
Aggregate annual costs are estimated at £26 billion (NHS
£3.4 billion, 13%; PSS £5.2 billion, 20%; unpaid care £15.8
billion, 61%; lost productivity £1.6 billion, 6%) (Table 2).
Costs for prevalent stroke are the main driver of aggregate
societal costs due to the much larger number of stroke
survivors (950,200) compared to new stroke cases each year
(117,600).
Unpaid care dominates forming 57 and 62% of costs of
incident and prevalent stroke, respectively. The contribution
of PSS costs doubles from 11% in the first year after stroke
to 22% in subsequent years, reflecting shifting patterns of
post-stroke care over time, i.e. reduced inputs from hospital
services and increased dependence on formal and unpaid
social care.
Discussion
Interpretation of findings
About, £26 billion represents a substantial cost impact in
both formal and unpaid care sectors. Productivity losses were
relatively small, but the trial data we drew on indicate that
these persist a year after stroke. Of particular note, unpaid
carers contribute substantially to stroke care.
Discussion of findings in context of existing evidence
Our estimates for NHS and social care costs align with
those obtained by Xu et al . [7], since we used their model
and underlying data for these cost domains. Drawing valid
comparisons with other cost-of-illness studies is challenging
given inevitable variations in methodology and context. For
some context, Smith et al . [25] reported total direct and
indirect costs of stroke for Ireland; while their total cost
estimates (0.5–0.8 billion Euros as a lower bound estimate
at 2007 prices) are lower due to smaller population size,
it is nevertheless interesting to note that the proportional
contributions to total costs were different. For example,
nursing home costs accounted for 44% of total costs, with
only 9% attributable to informal care. Wilkins et al . [26]
presented total health care costs for cerebrovascular diseases
at 2.6 billion Euros per year for the UK (2015 prices)
and 3.3 billion Euros for unpaid care and lost productivity.
Insufficient details prevent meaningful comparisons, but the
overall size of those figures and the proportion that might be
attributable to stroke is clearly substantially lower than ours.
Other estimates for aggregate annual costs in the UK
are less recent and also generated much lower totals of
£7 billion (2004 prices) for England [27] and £9 billion
(2005 prices) for the UK [5] from similar cost perspectives.
Using data now almost a decade older than used here, Saka
et al . [5] estimated direct medical care costs as £4.4 billion
compared to our estimate of £8.6 billion. More strikingly,
they calculated unpaid care at £2.4 billion per year, compared
to our £15.8 billion. Such differences may be driven by
several factors. For instance, their primary data (the SLSR)
represents a specific population and service context, and
unpaid care was estimated using different data sources and
estimation approaches.
Strengths and limitations
Our data sources are robust but do not reflect substantial
recent changes to stroke care. Impacts of these are mixed in
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Table 1. Mean cost of incident and prevalent stroke
NHS & PSS cost Unpaid care & lost productivity cost Total cost
Category Mean 95% CI Mean 95% CI Mean 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
First year cost (incident stroke)
All patients 18,081 17,621–18,542 27,328 24,434–30,221 45,409 42,054–48,763
Age (years)
40–64 12,770 12,089–13,451 33,191 26,567–39,815 45,961 38,656–53,266
65–74 15,577 14,742–16,412 25,800 21,351–30,248 41,377 36,093–46,660
75–84 20,011 19,201–20,820 27,487 22,924–32,050 47,497 42,124–52,870
≥85 22,961 21,892–24,029 18,234 11,274–25,194 41,195 33,166–49,223
Sex
Male 17,338 16,725–17,950 29,062 24,914–33,210 46,400 41,639–51,160
Female 18,824 18,198–19,451 25,090 21,196–28,984 43,914 39,394–48,435
Stroke type
Ischaemic 17,063 16,432–17,694 27,167 23,928–30,407 44,231 40,360–48,101
Haemorrhage 19,099 18,455–19,743 27,599 22,124–33,074 46,698 40,578–52,817
Subsequent year cost (prevalent stroke)
All patients 7,759 7,200–8,318 17,019 13,034–21,005 24,778 20,234–29,322
Age (years)
40–64 5,169 4,057–6,280 20,848 14,671–27,025 26,017 18,728–33,305
65–74 5,761 4,394–7,129 21,739 10,408–33,071 27,501 14,802–40,199
75–84 10,753 8,495–13,011 11,443 8,254–14,633 22,196 16,749–27,644
≥85 9,873 7,404–12,343 14,249 7,838–20,661 24,123 15,242–33,004
Sex
Male 7,221 5,741–8,701 18,681 12,308–25,053 25,901 18,049–33,754
Female 8,287 6,566–10,007 14,857 11,102–18,612 23,144 17,668–28,619
Stroke type
Ischaemic 7,225 5,750–8700 17,094 12,632–21,555 24,318 18,381–30,255
Haemorrhage 8,230 6,529–9931 18,315 9,855–26,775 26,545 16,384–36,706
Table 2. Aggregate cost of incident and prevalent stroke in the UK: base case, low- and high-cost estimates
Mean aggregate cost (£ million,
range†), base case estimates‡
Mean aggregate cost (£ million,
range), low estimates‡
Mean aggregate cost (£ million,
range), high estimates‡
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
First year cost (incident stroke)
NHS 1,560 (1138,1958) 1,535 (1120,1927) 1,585 (1156,1989)
Formal social care 565 (412,710) 521 (380,654) 610 (445,766)
Unpaid care 3,045 (2221,3822) 2,777 (2026,3486) 3,313 (2417,4158)
Lost productivity 168 (122,211) 95 (69,120) 240 (175,302)
NHS & PSS perspective 2,126 (1551,2668) 2,072 (1511,2600) 2,180 (1590,2736)
Societal perspective 5,340 (3896,6702) 4,945 (3608,6207) 5,734 (4183,7197)
Subsequent year cost (prevalent stroke)
NHS 1,844 (1576,2681) 1,762 (1506,2563) 1,925 (1645,2799)
Formal social care 4,616 (3945,6712) 4,174 (3567,6069) 5,058 (4322,7355)
Unpaid care 12,783 (10,925,18,588) 10,034 (8575,14,590) 15,532 (13,275,22,586)
Lost productivity 1,387 (1185,2016) 818 (699,1189) 1,955 (1671,2843)
NHS & PSS perspective 6,460 (5521,9393) 5,994 (5123,8717) 6,925 (5918,10,070)
Societal perspective 20,630 (17,632,29,999) 16,847 (14,398,24,497) 24,413 (20,865,35,500)
Incident and prevalent stroke cost
NHS 3,404 (2714,4639) 3,298 (2626,4490) 3,510 (2802,4789)
Formal social care 5,181 (4358,7422) 4,695 (3947,6724) 5,668 (4768,8121)
Unpaid care 15,828 (13,147,24,100) 12,811 (10,602,18,077) 18,845 (15,692,26,744)
Lost productivity 1,555 (1308,2228) 913 (769,1309) 2,196 (1847,3146)
NHS & PSS perspective 8,586 (7072,12,062) 8,066 (6635,11,317) 9,105 (7509,12,807)
Societal perspective 25,970 (21,528,26,701) 21,792 (18,006,30,704) 30,148 (25,049,42,698)
†Range based on low- and high-incidence and prevalence estimates. ‡Low- and high-cost estimates based on range of mean cost.
nature (e.g. increased short-term treatment costs, reduced
length of stay, greater rates of survival), so their overall
economic impact remains unclear. All cost-of-illness studies
also carry uncertainty in parameter values. Detailed unpaid
care and lost productivity data [9,10] represent the full eco-
nomic implications of stroke but may also overestimate costs
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because longer term costs may be lower than assessed during
the trial periods. Until improved precision in underlying data
can reduce estimation uncertainty, estimates should be taken
as indicative, rather than definitive.
Policy recommendations
Although significant progress in primary prevention and
urgent care has improved stroke incidence and survival,
there is scope to achieve more and to reduce costs for both
ischaemic and haemorrhagic stroke e.g. through better stroke
prevention. Substantial costs of stroke prevalence underline
gaps in evidence-based cost-effective rehabilitation interven-
tions [28], which could improve functioning and quality of
life, reduce stroke recurrence and reduce need for longer-
term care.
Greater policy support could help extend provision
already available and recommended in clinical guidelines,
but currently offered at sub-optimal levels risking inequitable
variations in care, health and quality of life, and also wasted
resources. For example, Xu et al . [7] estimated that each
extra person thrombolyzed or receiving early supported
discharge services could respectively generate NHS & PSS
savings of approximately £6000 or £4000 in just 1 year.
Similarly, reduced mortality and length of hospital stay
achieved in London through centralizing services to increase
delivery of effective urgent care could be replicated elsewhere
[29,30].
Finally, contributions from unpaid carers reduce pressures
on formal services but represent the transfer of significant
responsibilities, which can carry negative health, well-being
and economic consequences. It is thus important to assess
and meet carers’ own needs for support [31,32].
Conclusion
Inevitably, current resource constraints, system pressures and
practical hurdles create challenges for addressing the eco-
nomic impacts and associated issues. However, it is likely that
increased investments and a more co-ordinated approach
to care, and research [33], would go a long way towards
containing/reducing future impacts of stroke, improving
outcomes and reducing variations in stroke care.
Supplementary data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
Acknowledgements: We thank Xiang-Ming Xu and David
Wonderling at the National Guideline Centre for generously
sharing and explaining their economic model; Kate Holmes
and Shamim Quadir at the Stroke Association for support
and feedback throughout the project; William Day for pro-
viding support with focused literature reviews; our clinical
advisor, Anne Forster at University of Leeds, for advice and
support; and finally four anonymous peer reviewers who, on
behalf of the funders, provided enormously helpful feedback
on a draft report of this work.
Declaration of Conflicts of Interest: None.
Declaration of Funding: This work was supported by
the UK Stroke Association [TSA CR 2016/01]. Views
are authors’ own and not necessarily those of the Stroke
Association.
Guarantor: AP
Informed consent: Informed consent was not sought for
the present study because it used only secondary data in
aggregated form.
Ethical approval: Ethical approval was not sought for the
present study because it used only secondary data in aggre-
gated form.
References
1. TheGBD2016 Lifetime Risk of Stroke Collaborators. Global,
regional, and country-specific lifetime risks of stroke, 1990
and 2016. NEJM 2018; 379: 2429–37.
2. Rothwell PM, Coull AJ, Giles MF et al. Change in stroke
incidence, mortality, case-fatality, severity, and risk factors in
Oxfordshire, UK from 1981 to 2004 (Oxford vascular study).
Lancet 2004; 363: 1925–33.
3. Stroke Association. State of the nation: stroke statistics. Lon-
don: Stroke Association, 2016.
4. Geddes JM, Fear J, Tennant A et al. Prevalence of self reported
stroke in a population in northern England. J Epidemiol
Community Health 1996; 50: 140–3.
5. Saka O, McGuire A, Wolfe C. Cost of stroke in the United
Kingdom. Age Ageing 2009; 38: 27–32.
6. National Audit Office. Progress in improving stroke. Report
on the findings from our modelling of stroke care provision.
London: National Audit Office, 2010; (HC 291 2009-2010).
7. Xu XM, Vestesson E, Paley L et al. The economic burden of
stroke care in England, Wales and Northern Ireland: Using
a national stroke register to estimate and report patient-level
health economic outcomes in stroke. Eur Stroke J 2018; 3:
82–91.
9. Forster A, Dickerson J, Young J et al. A structured training
programme for caregivers of inpatients after stroke (TRACS):
A cluster randomised controlled trial and cost-effectiveness
analysis. Lancet 2013; 382: 2069–76.
10. Forster A, Young J, Chapman K et al. Cluster randomized
controlled trial: Clinical and cost-effectiveness of a system of
longer-term stroke care. Stroke 2015; 46: 2212–9.
11. Forster A, Dickerson J, Young J et al. A cluster randomised
controlled trial and economic evaluation of a structured train-
ing programme for caregivers of inpatients after stroke: The
TRACS trial. Health Technol Assess 2013; 17: 1–216.
12. Office for National Statistics. UK labour market: Feb 2017.
London: ONS, 2017.
13. Curtis L, Burns A. Unit costs of health and social care.
Canterbury: University of Kent, 2015.
14. Curtis L, Burns A. Unit costs of health and social care.
Canterbury: University of Kent, 2014.
275
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/a
g
e
in
g
/a
rtic
le
-a
b
s
tra
c
t/4
9
/2
/2
7
0
/5
6
7
9
6
8
4
 b
y
 g
u
e
s
t o
n
 1
8
 M
a
rc
h
 2
0
2
0
A. Patel et al.
15. Department of Health and Social Care. NHS Reference Costs
2014/15, 2015. https://www.gov.uk/government/publications/
nhs-reference-costs-2014-to-2015 (Accessed 6 December
2019).
17. Office for National Statistics. Population estimates for the
UK, England andWales, Scotland andNorthern Ireland: mid-
2016. London: ONS, 2016.
18. Wolfe CD, Rudd AG, Howard R et al. Incidence and case
fatality rates of stroke subtypes in a multiethnic population:
The South London stroke register. J Neurol Neurosurg Psy-
chiatry 2002; 72(2): 211–6.
19. Stewart JA, Dundas R, Howard RS et al. Ethnic differences
in incidence of stroke: Prospective study with stroke register.
BMJ 1999; 318(7189): 967–71.
20. Jagger C, Matthews R, Spiers N et al. Compression or expan-
sion of disability. London: King’s Fund, 2006.
21. O’Mahony PG,Thomson RG,Dobson R et al.Theprevalence
of stroke and associated disability. J Public Health Med 1999;
21(2): 166–71.
25. Smith S, Horgan F, Sexton E et al.The cost of stroke and tran-
sient ischaemic attack in Ireland: A prevalence-based estimate.
Age Ageing 2012; 41: 332–8.
26. Wilkins E, Wilson L, Wickramasinghe K et al. European
cardiovascular disease statistics. Brussels: EuropeanHeart Net-
work, 2017.
27. National Audit Office. Reducing brain damage: faster access
to better stroke care. London: National Audit Office,
2005.
28. Pollock A, St George B, Fenton M et al. Top ten research
priorities relating to life after stroke. Lancet Neurol 2012; 11:
209.
29. Morris S, Hunter RM, Ramsay AI et al. Impact of central-
ising acute stroke services in English metropolitan areas on
mortality and length of hospital stay: Difference-in-differences
analysis. BMJ 2014; 349: g4757.
30. Ramsay AI, Morris S, Hoffman A et al. Effects of centralizing
acute stroke services on stroke care provision in two
large metropolitan areas in England. Stroke 2015; 46:
2244–51.
31. Brimblecombe N, Fernandez J-L, Knapp M et al. Review of
the international evidence on support for unpaid carers. J
Long-Term Care 2018; 1: 25–40.
32. Adelman RD, Tmanova LL, Delgado D et al. Caregiver bur-
den: A clinical review. JAMA 2014; 311: 1052–60.
33. Luengo-Fernandez R, Leal J, Gray A. UK research spend in
2008 and 2012: Comparing stroke, cancer, coronary heart
disease and dementia. BMJ Open 2015; 5: e006648.
Received 6 August 2019; editorial decision 22 October
2019
276
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/a
g
e
in
g
/a
rtic
le
-a
b
s
tra
c
t/4
9
/2
/2
7
0
/5
6
7
9
6
8
4
 b
y
 g
u
e
s
t o
n
 1
8
 M
a
rc
h
 2
0
2
0
